骨转换标志物在骨质疏松症诊断与管理中作用的最新进展:欧洲骨质疏松、骨关节炎和肌肉骨骼疾病临床与经济学会(ESCEO)、国际骨质疏松基金会(IOF)和国际临床化学与实验室医学联合会(IFCC)的共识文件
该共识基于2011年IOF-IFCC立场文件后至2024年5月的文献,重申血清/血浆总PINP和血浆β-CTX-I作为骨质疏松症参考骨转换标志物,用于肾功能正常者的治疗监测;并推荐BALP和TRACP5b作为慢性肾脏病相关骨质疏松的参考标志物,需进一步研究其效用。
要点
- 骨转换标志物升高与绝经后女性骨折风险增高相关。
- PINP和β-CTX-I的变化可解释骨折风险降低的相当比例,并有助于改善依从性。
- 在晚期慢性肾脏病中,BALP、iPINP和TRACP5b在区分高/低骨转换、预测骨折风险等方面最具前景。
核心结论
- 重申血清/血浆总PINP和血浆β-CTX-I作为参考骨转换标志物,需规范患者准备、样本处理及标准化检测,用于临床研究中积累数据及肾功能正常者骨质疏松症的治疗监测。
- 推荐经标准化检测的BALP和TRACP5b作为慢性肾脏病相关骨质疏松的参考骨转换标志物,应纳入观察性和干预性研究以明确其在风险评估、治疗启动及疗效评估中的效用。
研究设计与样本
- 共识文件由ESCEO、IOF和IFCC制定,通过检索Medline数据库2011年至2024年5月的文献,综述骨转换标志物与骨折风险及治疗监测的证据。
主要发现
- 骨转换标志物浓度升高与绝经后女性较高的骨折风险相关。
- 血液中PINP和β-CTX-I与骨折风险相关,但其与其他风险因素的交互作用尚未充分研究,限制了其纳入骨折风险算法。
- 治疗引起的PINP和β-CTX-I变化可解释骨折风险降低的相当比例,并有助于改善依从性;建议将其纳入研究以检查个体患者的依从性。
- 在慢性肾脏病中,总PINP和β-CTX-I可能因肾脏潴留而升高。
- BALP、iPINP和TRACP5b在区分晚期慢性肾脏病患者高骨转换和低骨转换疾病、预测骨折风险、监测治疗反应及评估治疗相关并发症风险方面最具前景。
关键数值与推荐
- 推荐将血清/血浆总PINP和血浆β-CTX-I作为参考骨转换标志物,需规范患者准备、样本处理及标准化/协调检测,用于临床研究及肾功能正常者骨质疏松症的治疗监测。
- 推荐经标准化检测的BALP和TRACP5b作为慢性肾脏病相关骨质疏松的参考骨转换标志物,应纳入观察性和干预性研究。
临床怎么用
- 在肾功能正常者的临床实践中,可使用血清/血浆总PINP和血浆β-CTX-I监测骨质疏松症治疗。
- 对于慢性肾脏病相关骨质疏松,推荐使用经标准化检测的BALP和TRACP5b作为参考骨转换标志物,但其在风险评估、治疗启动及疗效评估中的效用尚需研究确定。
局限性
- PINP和β-CTX-I与其他风险因素的交互作用尚未充分研究,限制了其纳入骨折风险算法。
- 总PINP和β-CTX-I在慢性肾脏病中可能因肾脏潴留而升高。
- BALP和TRACP5b在慢性肾脏病相关骨质疏松中的效用需纳入观察性和干预性研究以确定。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The International Osteoporosis Foundation (IOF) and the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) have proposed procollagen type I N propeptide (PINP) and β isomerized C-terminal telopeptide of type I collagen (β-CTX-I) as reference bone turnover markers (BTMs) for osteoporosis. This report examines the published literature since the 2011 IOF-IFCC position paper in order to determine the clinical potential of the reference BTMs and newer markers for the prediction of fracture risk and monitoring the treatment of osteoporosis. METHODS: Evidence for the relationship between BTMs and subsequent fractures was gathered from prospective studies through literature review of the Medline database from years 2011 to May 2024. The impact of treatment on BTMs was also studied by examining publications in that period. Studies of the accuracy of BTMs in the assessment of bone turnover in the setting of advanced chronic kidney disease were also examined. RESULTS: Increased BTM concentrations are associated with higher fracture risk in postmenopausal women. PINP and β-CTX-I measured in blood are associated with fracture risk but their interaction with other risk factors has not been sufficiently studied limiting their incorporation into fracture risk algorithms. Treatment-induced changes in PINP and β-CTX-I account for a substantial proportion of fracture risk reduction and are useful for improving adherence; they are recommended for inclusion in studies to examine adherence in individual patients. However, total PINP (tPINP) and β-CTX-I may be elevated in CKD due to renal retention. Bone alkaline phosphatase (BALP), intact PINP (iPINP), and tartrate resistant acid phosphatase 5b (TRACP5b) show the most promise in discriminating high and low turnover bone diseases in patients with advanced CKD and for predicting fracture risk, monitoring treatment response, and assessing the risk of treatment-related complications. CONCLUSION: We re-affirm the use of serum/plasma tPINP and plasma β-CTX-I as reference BTMs with appropriate patient preparation and sample handling and measurement by standardized/harmonized assays in clinical studies to accumulate further data, and for monitoring treatment of osteoporosis in the setting of normal renal function in clinical practice. BALP and TRACP5b, measured by standardized assays, are recommended as reference BTMs for CKD-associated osteoporosis and should be included in observational and intervention studies to ascertain their utility for risk-evaluation, treatment initiation, and assessment of treatment response in CKD-associated osteoporosis.
引用
- Bhattoa HP, Vasikaran S, Trifonidi I, et al. Update on the role of bone turnover markers in the diagnosis and management of osteoporosis: a consensus paper from The European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO), International Osteoporosis Foundation (IOF), and International Federation of Clinical Chemistry and Laboratory Medicine (IFCC). Osteoporos Int. 2025. PMID: 40152990. doi:10.1007/s00198-025-07422-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。